Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Ascidian Therapeutics Scores $40M in Series A Extension

2023-11-08
BOSTON, MA, Ascidian Therapeutics, a biotechnology company, announced $40 million in Series A extension funding committed by Apple Tree Partners.
Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced $40 million in Series A extension funding committed by Apple Tree Partners (ATP). This financing follows ATP's initial $50 million Series A investment in Ascidian announced in October 2022.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors